StockpollyBeta
Get App
Popularity #2,574
SEPN · NASDAQ · Biotechnology

Septerna (SEPN)

Develops oral GPCR drug candidates using its Native Complex Platform.

$40.38
After-hours close0.00 (0.00%)
At close$40.38(+4.77%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue0000000021242727
Cost of revenue000000000000
Gross profit0000000021242627
12−3416182325262919403944
Research & development91013151819192224322935
3333567778108
General & administrative3333567778108
Other expenses0−48000000−13000
Operating income−1234−15−18−23−25−26−293−16−13−17
111224446555
Interest income111224446555
Other non-operating income−148−1−2−2−4−4−413−5−5−5
Income before tax−1136−14−17−21−21−21−258−11−8−12
Income tax expense010000000001
Net income from continuing operations−1135−14−16−21−21−21−258−11−9−13
Net income−1135−14−16−21−21−21−258−11−9−13
EPS, basic−$0.56$2.07−$0.34−$0.39−$0.49−$0.64−$0.49−$0.56$0.18−$0.24−$0.19−$0.29
EPS, diluted−$0.56$2.05−$0.34−$0.39−$0.49−$0.64−$0.49−$0.56$0.18−$0.24−$0.19−$0.29
Weighted average shares, basic191742424232444444444545
Weighted average shares, diluted191742424232444446444545
EBITDA−11−13−14−16−20−20−21−24−9−10−8−12
Depreciation & amortization000000000000
EBIT−11−13−14−17−21−21−21−25−10−11−8−12